![](https://medcitynews.com/uploads/2021/07/GettyImages-1280895783-150x150.jpg)
biomarkers
-
MedCity Influencers, Diagnostics, Health Tech
How vocal biomarkers are becoming a necessary tool for remote patient monitoring
With the information contained in a simple 30-second voice sample, providers can help patients get ahead of future health issues and prescribe or adjust treatment plans as needed.
-
MedCity Influencers, BioPharma
Discovering biomarkers to find new ways to treat diseases of unmet need
Blending computational biology and AI-based methods, the goal is to identify new targets, pair these with effective chemistry, and define biomarkers to optimally position novel therapies.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Artificial Intelligence, Health Tech
DoD tests wearables’ ability to detect Covid-19 before symptoms appear
Before the pandemic started, the U.S. Department of Defense and Philips designed a system to detect potential infections before symptoms appear. Now, they’re turning it on the Covid-19 pandemic.
-
Merck cancer immunotherapy drug gets expansion to biomarker-based labeling
The FDA approved Keytruda as a single agent for patients with first-line metastatic or unresectable colorectal cancer that carries the biomarker MSI-H or dMMR. The drug was the first to win a biomarker-based, tumor-agnostic label, in 2017.
-
Syapse, NCCN partner to incorporate cancer biomarker data into precision medicine software
Integrating the NCCN’s Biomarker Compendium data into Syapse’s products is designed to aid finding targeted drugs and clinical trials while improving physician workflow.
-
Global market for cancer biomarkers set to reach $20.48 billion in four years
Forecast of significant growth in market comes after Roche acquired remaining stake in Foundation Medicine last month.
-
FDA accepts Loxo approval application for biomarker-driven cancer drug
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck’s Keytruda.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Takeaways from digital health progress report include wider adoption by pharma, healthcare
The number of digital health apps has doubled in recent years to 318,000. Increased clinical validation has led to wider adoption of apps and sensors by pharma companies and healthcare systems to remotely monitor patients and quantify medication adherence.
-
Digital biomarkers: Lots of potential, but where’s the validation?
There’s still a gap between potential and validation when it comes to digital biomarkers.
-
Global biomarker market projected to reach $53.6B by 2020
The biomarker market is booming, and it’s projected to keep soaring significantly.